real repetitive transcranial magnetic stimulation (rTMS)sham repetitive transcranial magnetic stimulation (rTMS)cognitive strategy training
real repetitive transcranial magnetic stimulation (rTMS): real rTMS -- 3 sessions a week/7 weeks (21 sessions)
sham repetitive transcranial magnetic stimulation (rTMS): sham rTMS - 3 sessions a week/7 weeks (21 sessions)
cognitive strategy training: 7 weekly sessions with a trained neuropsychologist.
Study summary
The TRUE-GRIT study will assess the feasibility of a study protocol investigating the efficacy of a combination therapy consisting of cognitive strategy training (CST) and repetitive transcranial magnetic stimulation (rTMS) to reduce cognitive impairment in adult glioma patients. This study is part of the GRIP-project, a project aimed at investigating interventions for improving quality of life in brain tumor patients.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* ≥ 18 years of age
* Histological diagnosis of diffuse glioma (WHO grade 2,3, or 4)
* Subjective cognitive impairment, defined as CFQ-score ≥ 44
* Being able to give informed consent and undergo treatment and measurements based on researchers insight
* Stable disease, i.e. no oncological treatment for ≤ 2 months prior to inclusion; no radiological progression on the most recent MRI, not older than 6 months, and no clinical progression at inclusion
* Stable dosage (for at least 8 weeks) of anti-epileptic medication
Exclusion Criteria:
* Current pregnancy or have given birth less than three months ago
* Current other treatment for cognitive complaints
* Karnofsky performance score \<70
* A tumor located in the parietal cortex
* TMS exclusion: implanted medical devices (e.g. pacemaker, deep brain stimulator, cochlear implants, medical infusion device, etc.); metal in the body; sleep deprivation
* MRI exclusion: extreme claustrophobia or metallic objects in or on the body
Primary outcome measure(s)
Number of patients completing intervention and study protocol — Baseline versus directly post-intervention (max. 11 weeks after baseline) The feasibility will be assessed by number of patients completing the intervention and obligatory study measurements
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
